Clinical Trial Payment Tax Exclusion Act

Summary#

The bill would change federal tax and benefit rules for people who take part in clinical trials. It would make most payments to clinical trial participants tax-free and require those payments not to be counted as income or resources when deciding eligibility for federal programs or for state/local programs that get federal money. The law would apply to payments made after December 31, 2025.

• Main change: Creates a new federal tax exclusion for "qualified clinical trial payment" — payments for participating in, or reimbursements of reasonable expenses related to, an approved clinical trial.
• Definition of approved trial: Uses the existing Public Health Service Act definition of an approved clinical trial, but broadens it by replacing the phrase “life‑threatening disease or condition” with “disease or condition.”
• Benefit rules: Says such payments must not be counted as income or resources for eligibility or benefit amounts under any federal program or any state/local program that is funded in whole or in part with federal funds.
• Who counts as a dependent: The bill uses the existing tax code definition of dependent for payments related to a dependent’s participation.
• Effective date: Applies to amounts paid after December 31, 2025.
• What is unclear: The bill does not set dollar limits, list exactly which expense types qualify, or explain documentation or verification steps for tax or benefit administrators.

What it means for you#

• Clinical trial participants

  • Payments you receive for joining an approved clinical trial would not be included in your federal taxable income.
  • Reimbursements for reasonable and necessary trial-related expenses (for you or an eligible dependent) would also be excluded from federal income tax.

• Family members and dependents

  • Payments made because a dependent participated in a qualifying trial would be excluded from the family’s taxable income, using the tax code’s existing dependent rules.

• People applying for federally funded benefits

  • If you get payments that qualify, those amounts would not be counted as income or resources when agencies check your eligibility for federal programs or for state/local programs that use federal funds.
  • This could affect determinations for means-tested programs (for example, programs that look at income or assets), though the bill does not list specific programs.

• Researchers and trial sponsors

  • Payments and reimbursements they make to participants would become tax-exempt for recipients, which could change how sponsors budget and report payments.

• Tax and benefit agencies

  • IRS and benefit administrators would need to adopt procedures to recognize and exclude qualified clinical trial payments when computing taxable income and program eligibility.

Expenses#

No publicly available information.

• Possible loss of federal tax revenue because some payments that are now likely taxable would be excluded.
• Potential administrative costs for the IRS and for federal, state, and local benefit agencies to update rules, systems, and training to implement the exclusion and the exclusion from eligibility calculations.
• Possible compliance costs for clinical trial sponsors to track and document payments as qualifying under the new rule.
• It is not specified whether states must change eligibility rules for programs that are not federally funded.

Proponents' View#

• The bill appears intended to remove financial barriers to joining clinical trials by making participation payments and expense reimbursements tax-free.
• This could make it easier for participants to accept compensation without risking higher taxes or losing eligibility for benefits.
• The change may encourage more people to join clinical trials, which could help research and medical development.
• Excluding reimbursements for reasonable expenses could reduce the out-of-pocket cost of participating in trials.

Opponents' View#

• One concern is that excluding these payments from taxable income would reduce federal revenue; the bill does not include an estimate of that cost.
• The bill does not set dollar limits or clear documentation rules, so there could be uncertainty about what counts as a qualifying payment or expense.
• Verifying whether a trial is an “approved clinical trial” may create administrative work for agencies. The bill adopts a statutory definition but changes one phrase, which could raise questions about which studies qualify.
• States and local programs that receive federal funds would have to change eligibility rules or procedures; implementing those changes could be complex and costly.
• Without clearer rules, there is a risk of inconsistent treatment across tax filings and benefit programs.